The $1 Billion Bet on Editing Cholesterol Once - Then Never Again

Verve Therapeutics spent seven years turning a genetic observation into a one-infusion cholesterol treatment. Its first delivery system stumbled; the replacement helped sell the company to Lilly and may redraw the boundary between a drug and a permanent decision.